Viatris has received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low-dose estrogen contraceptive patch with data supporting its efficacy and safety. This approval adds a branded asset to Viatris' women's health portfolio and may influence its U.S. market position. The stock has shown strong momentum, with a share price of $17.56, a 40.9% return year to date, and a 107.2% return over the past year.
Viatris IncFDA approval for Gwyn Lo contraceptive patch adds a branded asset to Viatris' women's health portfolio.